Kailera Therapeutics, Inc.
No enriched coverage for $KLRA in the last 7 days.
No SEC Form 4 filings for $KLRA in the last 30 days.
See all $KLRA insider activity →Kailera Therapeutics, Inc. (KLRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0002096997-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates • IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 • Ribu
The article highlights Novo Nordisk (NVO) and Kailera Therapeutics (KLRA) as GLP-1-related stocks. Novo Nordisk launched oral Wegovy in January; it has surpassed 3 million U.S. prescriptions and received EU approval, contributing to better-than-expected Q1 results. Kailera, down 23% since its April IPO, reported phase 3 results in China for oral KAI-7535, with up to 11.1% mean weight loss after 50 weeks.
Kailera Therapeutics (NASDAQ:KLRA) reported positive topline Phase 3 results for HRS-7535/KAI-7535, an oral GLP-1 receptor agonist, in obesity and type 2 diabetes trials. Obesity participants saw mean weight loss up to 10.9% by Week 44 and 11.1% by Week 50; HbA1c fell 1.50% to 1.68%. Safety showed no new signals. KLRA is also running a global Phase 2 trial starting April 2026, with results expected in 2027.
Recent KLRA coverage spans earnings, sector analysis and technology.
New clinical and regulatory execution milestones (U.S. IND active, Phase 3 timing, Phase 2b enrollment completion) can shift probability-weighted timelines and near-term funding runway expectations.
Potentially bullish catalyst if U.S. late-stage execution matches China data, but high execution risk remains.
Positive Phase 3 topline efficacy and consistent liver safety are a near-term catalyst for KLRA sentiment and valuation expectations.
alphai scores every news story that mentions KLRA with an AI model for sentiment and relevance, and aggregates insider trades from Kailera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kailera Therapeutics, Inc. (KLRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0002096997-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates • IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 • Ribu
6 min readThe article highlights Novo Nordisk (NVO) and Kailera Therapeutics (KLRA) as GLP-1-related stocks. Novo Nordisk launched oral Wegovy in January; it has surpassed 3 million U.S. prescriptions and received EU approval, contributing to better-than-expected Q1 results. Kailera, down 23% since its April IPO, reported phase 3 results in China for oral KAI-7535, with up to 11.1% mean weight loss after 50 weeks.
7 min readKailera Therapeutics (NASDAQ:KLRA) reported positive topline Phase 3 results for HRS-7535/KAI-7535, an oral GLP-1 receptor agonist, in obesity and type 2 diabetes trials. Obesity participants saw mean weight loss up to 10.9% by Week 44 and 11.1% by Week 50; HbA1c fell 1.50% to 1.68%. Safety showed no new signals. KLRA is also running a global Phase 2 trial starting April 2026, with results expected in 2027.
3 min read
